EUVIMEDEUVIMED entdecken
Crossref

Desmoplakin I/ II immunohistochemical staining may be a helpful tool in differentiating cutaneous graft versus host disease from the erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis spectrum disorders

Trent Irwin iD, Cecilia C S Yeung, Michi M Shinohara

Journal of Cutaneous Pathology · 2024

DOI: 10.1111/cup.14513 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cutaneous Pathology, 2024. Verfasst von Trent Irwin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Stevens-Johnson Syndrome, Erythema Multiforme, Graft vs Host Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: University of Washington.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous graft versus host disease (cGVHD) has substantial clinical and histopathologic overlap with erythema multiforme (EM), Stevens–Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). This overlap can make it difficult to distinguish these disorders in patients who have received hematopoietic transplants. We sought to evaluate the utility of Dp I/II immunohistochemical stain in differentiating EM/SJS/TEN and cGVHD in a large cohort. Skin biopsy specimens from patients with cGVHD ( n = 58) and EM/SJS/TEN ( n = 60) were evaluated for Dp I/II expression by immunohistochemistry. We found a statistically significant difference in Dp I/II staining between cGVHD (all grades) and EM/SJS/TEN (mean scores 1.62 and 2.14, respectively; p < 0.005), as well as between Grades 2 + 3 cGVHD and EM/SJS/TEN (mean scores 2.26 and 1.62, respectively; p < 0.005), while we did not find a significant difference between Grade 4 cGVHD and EM/SJS/TEN (mean scores 1.69 and 1.62, respectively; p = 0.71). Dp I/II immunostain may be useful for differentiating EM/SJS/TEN from Grade 2 and Grade 3 cGVHD, especially in clinically ambiguous cases without extracutaneous GVHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stevens-Johnson SyndromeErythema MultiformeGraft vs Host DiseaseHumansDesmoplakinsStaining and Labeling

Stichwörter der Autor:innen

Stevens-Johnson syndromecutaneous graft versus host diseasedesmoplakinerythema multiformeimmunohistochemistrytoxic epidermal necrolysis

Substanzen

Desmoplakins

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Division of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Trent Irwin

Förderung

  • University of Washington

Zitieren

APA

Irwin, T., Yeung, C. C. S., & Shinohara, M. M. (2024). Desmoplakin I/ II immunohistochemical staining may be a helpful tool in differentiating cutaneous graft versus host disease from the erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis spectrum disorders. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14513

Vancouver

Irwin T, Yeung CCS, Shinohara MM. Desmoplakin I/ II immunohistochemical staining may be a helpful tool in differentiating cutaneous graft versus host disease from the erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis spectrum disorders. Journal of Cutaneous Pathology. 2024. doi:10.1111/cup.14513

BibTeX
@article{Irwin2024,
  author = {Irwin, Trent and Yeung, Cecilia C S and Shinohara, Michi M},
  title = {Desmoplakin I/ II immunohistochemical staining may be a helpful tool in differentiating cutaneous graft versus host disease from the erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis spectrum disorders},
  journal = {Journal of Cutaneous Pathology},
  year = {2024},
  doi = {10.1111/cup.14513}
}
Kostenlos starten →